PDCD1 and cancer: In summary, inhibiting COX2 activity was more effective in unleashing the antitumor potential of CDA than simultaneous disruption of the PD-1 and IDO pathways that commonly contribute to ICPs and promote therapy resistance in many patients with cancer and mouse tumor models.